The Filings Report

IDEXX Laboratories

IDXXNasdaqCIK 874716Healthcare / Diagnostics & Researchfiscal year ends December69 quarters since 2009

Revenue, Q2 FY2026
$1.2B
+9.7% on Q2 FY2025
Net income
$338M
+15.1% on Q2 FY2025
Free cash flow
$323M
+112.7% on Q2 FY2025
Diluted EPS
$4.27
+17.6% on Q2 FY2025
Revenue, TTM
$4.6B
trailing four quarters
Net margin, TTM
25.0%
net income $1.1B
Free cash flow, TTM
$1.3B
$1.4B less $117M capex
Cash and equivalents
$197M
long-term debt $300M, Jun 30, 2026
Shares, 12-month change
−1.5%
79M shares, Jun 30, 2026
Buybacks, TTM
$1.2B
2.7% of market value
Dividends, TTM
—
no yield
Market value
$43.4B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 4, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, IDEXX Laboratories reported revenue of $1.2B, +9.7% on Q2 FY2025, and net income of $338M (+15.1%). Operating margin was 35.0%. Free cash flow, operating cash flow less capital expenditures, was $323M ($347M less $25M). Diluted earnings per share were $4.27.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 4, 2026.

Revenue and net incomeRevenueNet income
$0$500M$1.0B$1.5BQ3'22, Revenue: $842MQ3'22, Net income: $181MQ3'22Q4'22, Revenue: $829MQ4'22, Net income: $172MQ4'22Q1'23, Revenue: $900MQ1'23, Net income: $214MQ1'23Q2'23, Revenue: $944MQ2'23, Net income: $224MQ2'23Q3'23, Revenue: $916MQ3'23, Net income: $212MQ3'23Q4'23, Revenue: $902MQ4'23, Net income: $195MQ4'23Q1'24, Revenue: $964MQ1'24, Net income: $236MQ1'24Q2'24, Revenue: $1.0BQ2'24, Net income: $203MQ2'24Q3'24, Revenue: $976MQ3'24, Net income: $233MQ3'24Q4'24, Revenue: $954MQ4'24, Net income: $216MQ4'24Q1'25, Revenue: $998MQ1'25, Net income: $243MQ1'25Q2'25, Revenue: $1.1BQ2'25, Net income: $294MQ2'25Q3'25, Revenue: $1.1BQ3'25, Net income: $275MQ3'25Q4'25, Revenue: $1.1BQ4'25, Net income: $248MQ4'25Q1'26, Revenue: $1.1BQ1'26, Net income: $278MQ1'26Q2'26, Revenue: $1.2BQ2'26, Net income: $338MQ2'26$0$500M$1.0B$1.5BQ3'22, Revenue: $842MQ3'22, Net income: $181MQ4'22, Revenue: $829MQ4'22, Net income: $172MQ4'22Q1'23, Revenue: $900MQ1'23, Net income: $214MQ2'23, Revenue: $944MQ2'23, Net income: $224MQ2'23Q3'23, Revenue: $916MQ3'23, Net income: $212MQ4'23, Revenue: $902MQ4'23, Net income: $195MQ4'23Q1'24, Revenue: $964MQ1'24, Net income: $236MQ2'24, Revenue: $1.0BQ2'24, Net income: $203MQ2'24Q3'24, Revenue: $976MQ3'24, Net income: $233MQ4'24, Revenue: $954MQ4'24, Net income: $216MQ4'24Q1'25, Revenue: $998MQ1'25, Net income: $243MQ2'25, Revenue: $1.1BQ2'25, Net income: $294MQ2'25Q3'25, Revenue: $1.1BQ3'25, Net income: $275MQ4'25, Revenue: $1.1BQ4'25, Net income: $248MQ4'25Q1'26, Revenue: $1.1BQ1'26, Net income: $278MQ2'26, Revenue: $1.2BQ2'26, Net income: $338MQ2'26

Net income losses drawn in red.

Free cash flow
$0$100M$200M$300M$400MQ3'22, Free cash flow: $151MQ3'22Q4'22, Free cash flow: $124MQ4'22Q1'23, Free cash flow: $144MQ1'23Q2'23, Free cash flow: $173MQ2'23Q3'23, Free cash flow: $238MQ3'23Q4'23, Free cash flow: $217MQ4'23Q1'24, Free cash flow: $168MQ1'24Q2'24, Free cash flow: $215MQ2'24Q3'24, Free cash flow: $192MQ3'24Q4'24, Free cash flow: $233MQ4'24Q1'25, Free cash flow: $208MQ1'25Q2'25, Free cash flow: $152MQ2'25Q3'25, Free cash flow: $371MQ3'25Q4'25, Free cash flow: $326MQ4'25Q1'26, Free cash flow: $234MQ1'26Q2'26, Free cash flow: $323MQ2'26$0$100M$200M$300M$400MQ3'22, Free cash flow: $151MQ4'22, Free cash flow: $124MQ4'22Q1'23, Free cash flow: $144MQ2'23, Free cash flow: $173MQ2'23Q3'23, Free cash flow: $238MQ4'23, Free cash flow: $217MQ4'23Q1'24, Free cash flow: $168MQ2'24, Free cash flow: $215MQ2'24Q3'24, Free cash flow: $192MQ4'24, Free cash flow: $233MQ4'24Q1'25, Free cash flow: $208MQ2'25, Free cash flow: $152MQ2'25Q3'25, Free cash flow: $371MQ4'25, Free cash flow: $326MQ4'25Q1'26, Free cash flow: $234MQ2'26, Free cash flow: $323MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$200M$400M$600M$800MQ3'22, Cash and equivalents: $99MQ3'22, Long-term debt: $761MQ3'22Q4'22, Cash and equivalents: $113MQ4'22, Long-term debt: $694MQ4'22Q1'23, Cash and equivalents: $111MQ1'23, Long-term debt: $696MQ1'23Q2'23, Cash and equivalents: $133MQ2'23, Long-term debt: $697MQ2'23Q3'23, Cash and equivalents: $332MQ3'23, Long-term debt: $619MQ3'23Q4'23, Cash and equivalents: $454MQ4'23, Long-term debt: $623MQ4'23Q1'24, Cash and equivalents: $397MQ1'24, Long-term debt: $621MQ1'24Q2'24, Cash and equivalents: $402MQ2'24, Long-term debt: $525MQ2'24Q3'24, Cash and equivalents: $309MQ3'24, Long-term debt: $525MQ3'24Q4'24, Cash and equivalents: $288MQ4'24, Long-term debt: $450MQ4'24Q1'25, Cash and equivalents: $164MQ1'25, Long-term debt: $450MQ1'25Q2'25, Cash and equivalents: $165MQ2'25, Long-term debt: $450MQ2'25Q3'25, Cash and equivalents: $208MQ3'25, Long-term debt: $375MQ3'25Q4'25, Cash and equivalents: $180MQ4'25, Long-term debt: $375MQ4'25Q1'26, Cash and equivalents: $201MQ1'26, Long-term debt: $300MQ1'26Q2'26, Cash and equivalents: $197MQ2'26, Long-term debt: $300MQ2'26$0$200M$400M$600M$800MQ3'22, Cash and equivalents: $99MQ3'22, Long-term debt: $761MQ4'22, Cash and equivalents: $113MQ4'22, Long-term debt: $694MQ4'22Q1'23, Cash and equivalents: $111MQ1'23, Long-term debt: $696MQ2'23, Cash and equivalents: $133MQ2'23, Long-term debt: $697MQ2'23Q3'23, Cash and equivalents: $332MQ3'23, Long-term debt: $619MQ4'23, Cash and equivalents: $454MQ4'23, Long-term debt: $623MQ4'23Q1'24, Cash and equivalents: $397MQ1'24, Long-term debt: $621MQ2'24, Cash and equivalents: $402MQ2'24, Long-term debt: $525MQ2'24Q3'24, Cash and equivalents: $309MQ3'24, Long-term debt: $525MQ4'24, Cash and equivalents: $288MQ4'24, Long-term debt: $450MQ4'24Q1'25, Cash and equivalents: $164MQ1'25, Long-term debt: $450MQ2'25, Cash and equivalents: $165MQ2'25, Long-term debt: $450MQ2'25Q3'25, Cash and equivalents: $208MQ3'25, Long-term debt: $375MQ4'25, Cash and equivalents: $180MQ4'25, Long-term debt: $375MQ4'25Q1'26, Cash and equivalents: $201MQ1'26, Long-term debt: $300MQ2'26, Cash and equivalents: $197MQ2'26, Long-term debt: $300MQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

IDEXX Laboratories income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 21, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue1,2171,1411,0911,1051,109998954976+9.7%
Cost of revenue437418432422415375384380+5.5%
Gross profit779723658683695623571596+12.1%
Research and development6566676362595854+5.7%
Selling, general and administrative117119109106999210192+18.4%
Operating income426363316355373317262304+14.1%
Other income (expense)—————————
Pretax income417355307345362310256299+15.1%
Income tax7977597068674066+15.3%
Net income338278248275294243216233+15.1%
Diluted EPS ($)4.273.47—3.403.632.96—2.80+17.6%
Diluted shares (millions)7980—818182—83—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

IDEXX Laboratories balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 21, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents197201180208165164288309+19.6%
Short-term investments—————————
Total current assets1,5091,4541,4141,4771,3621,3181,4001,434+10.8%
Total assets3,4423,3853,3513,3873,3313,2143,2933,351+3.3%
Total current liabilities1,2881,3001,1491,2521,2241,1361,0681,009+5.2%
Long-term debt300300375375450450450525−33.3%
Total liabilities1,8301,8291,7451,8261,8721,7661,6981,733−2.3%
Stockholders’ equity1,6131,5561,6051,5611,4591,4481,5951,618+10.5%
Shares outstanding (millions)7979808080808182—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

IDEXX Laboratories cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 21, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow347266356402186238262220+86.9%
Capital expenditures2532293134302928−27.7%
Free cash flow (CFO − capex)323234326371152208233192+112.7%
Depreciation and amortization4138393736343434+14.8%
Share repurchases347351238240338401246221+2.6%
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 20, 2026.

Income statement

IDEXX Laboratories income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 21, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 16, 2023FY2021ended Dec 31, 2021filed Feb 16, 2022FY2020ended Dec 31, 2020filed Feb 12, 2021FY2019ended Dec 31, 2019filed Feb 14, 2020FY2018ended Dec 31, 2018filed Feb 15, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 17, 2016FY2014ended Dec 31, 2014filed Feb 17, 2015FY2013ended Dec 31, 2013filed Feb 18, 2014FY2012ended Dec 31, 2012filed Feb 19, 2013FY2011ended Dec 31, 2011filed Feb 17, 2012FY2010ended Dec 31, 2010filed Feb 22, 2011FY2009ended Dec 31, 2009filed Jul 23, 2010FY2008ended Dec 31, 2008filed Jul 23, 2010
Revenue4,3043,8983,6613,3673,2152,7072,4072,2131,9691,7751,6021,4861,3771,2931,2191,1031,0321,024
Cost of revenue1,6441,5191,4711,3631,3261,1361,041972872800712670621594572525505494
Gross profit2,6602,3792,1902,0041,8891,5711,3661,2421,097975890816756699647579526530
Research and development25122019125516114113311810910110098888276696571
Selling, general and administrative405442336326310301261245221207183174158138129127117117
Operating income1,3601,1281,097899932695553491413350300260267263236204176172
Other income (expense)——————————————————
Pretax income1,3241,1101,061860903662522458381322273247263261234202175170
Income tax2652222161811588094811181008165758273615254
Net income1,059888845679745582428377263222192182188178162141122116
Diluted EPS ($)13.0810.6710.068.038.606.714.894.262.942.442.051.791.741.58*1.39*1.19*1.00*0.94*
Diluted shares (millions)8183848587878888909194102108112*116*119*121*124*

Balance sheet

IDEXX Laboratories balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 21, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 16, 2023FY2021ended Dec 31, 2021filed Feb 16, 2022FY2020ended Dec 31, 2020filed Feb 12, 2021FY2019ended Dec 31, 2019filed Feb 14, 2020FY2018ended Dec 31, 2018filed Feb 15, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 17, 2016FY2014ended Dec 31, 2014filed Feb 17, 2015FY2013ended Dec 31, 2013filed Feb 18, 2014FY2012ended Dec 31, 2012filed Feb 19, 2013FY2011ended Dec 31, 2011filed Feb 17, 2012FY2010ended Dec 31, 2010filed Feb 22, 2011FY2009ended Dec 31, 2009filed Jul 23, 2010FY2008ended Dec 31, 2008filed Jul 23, 2010
Cash and equivalents1802884541131443849012418815512932327922418415710779
Short-term investments———————0284237214———————
Total current assets1,4141,4001,4951,1019561,063680653972846822759653570524461376—
Total assets3,3513,2933,2602,7472,4372,2951,8321,6201,7421,5311,4751,3841,2311,1041,031897809—
Total current liabilities1,1491,0689521,2367645837257841,005935857821478406437285256—
Long-term debt37545062369477585869960260759459735015133———
Total liabilities1,7451,6981,7752,1381,7471,6621,6551,6291,8011,6391,5591,267712467491323294—
Stockholders’ equity1,6051,5951,485609690632177(10)(54)(108)(84)118518636540574515—
Shares outstanding (millions)808183838485858687889094*103*109*110*115*——

Cash flow statement

IDEXX Laboratories cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 21, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 16, 2023FY2021ended Dec 31, 2021filed Feb 16, 2022FY2020ended Dec 31, 2020filed Feb 12, 2021FY2019ended Dec 31, 2019filed Feb 14, 2020FY2018ended Dec 31, 2018filed Feb 15, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 17, 2016FY2014ended Dec 31, 2014filed Feb 17, 2015FY2013ended Dec 31, 2013filed Feb 18, 2014FY2012ended Dec 31, 2012filed Feb 19, 2013FY2011ended Dec 31, 2011filed Feb 17, 2012FY2010ended Dec 31, 2010filed Feb 22, 2011FY2009ended Dec 31, 2009filed Jul 23, 2010FY2008ended Dec 31, 2008filed Jul 23, 2010
Operating cash flow1,182929907543756648459400373——236246222218179175143
Capital expenditures12512113414912010715511674658361785850395190
Free cash flow (CFO − capex)1,057808773394636541304284299——17516816516814012453
Depreciation and amortization14513011511210596888383786959555248465048
Share repurchases1,2178377282074718330236928330440261836813225614383132
Dividends paid——————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$1M
1 sales by 1 insider; officers and directors $1M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$38M
36 sales by 6 insiders; officers and directors $38M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 4, 2026Kingsley Lawrence DDirectoroption exercise2,203$114.17$252K11,771Sep 9, 2026
Sep 4, 2026Kingsley Lawrence DDirectoropen-market sale2,203$532.08$1M9,568Sep 9, 2026
Aug 20, 2026Emerson AndrewEVP, CFO and Treasureroption exercise265$178.26$47K4,507Aug 24, 2026
Aug 20, 2026Emerson AndrewEVP, CFO and Treasurertax withholding86$0.00—4,421Aug 24, 2026
Jul 30, 2026Hooley Joseph LDirectoraward49$558.80$27K325Aug 3, 2026
Jun 1, 2026Fennell GeorgeExecutive Vice Presidentoption exercise639$0.00—10,717Jun 2, 2026
Jun 1, 2026Fennell GeorgeExecutive Vice Presidenttax withholding284$566.79$161K10,433Jun 2, 2026
May 7, 2026Vandebroek Sophie V.Directoroption exercise257$0.00—905May 11, 2026
May 7, 2026Szostak M AnneDirectoroption exercise257$0.00—519May 11, 2026
May 7, 2026Peacock KarenDirectoroption exercise101$0.00—102May 11, 2026
May 7, 2026Kingsley Lawrence DDirectoroption exercise257$0.00—9,486May 11, 2026
May 7, 2026Kingsley Lawrence DDirectoroption exercise82$0.00—9,568May 11, 2026
May 7, 2026Junius Daniel MDirectoroption exercise257$0.00—3,561May 11, 2026
May 7, 2026Hooley Joseph LDirectoroption exercise158$0.00—276May 11, 2026
Apr 30, 2026Hooley Joseph LDirectoraward43$560.80$24K118May 4, 2026
Mar 3, 2026Underberg Sharon E.EVP, GC & Corporate Secretaryoption exercise197$505.53$100K7,138Mar 5, 2026
Mar 3, 2026Hunt NimrataExecutive Vice Presidentopen-market sale1,758$634.57$1M18,141Mar 5, 2026
Feb 27, 2026Mazelsky Jonathan JayPresident and CEO, Directoroption exercise197$505.53$100K83,803Mar 2, 2026
Feb 26, 2026Mazelsky Jonathan JayPresident and CEO, Directoropen-market sale2,860$657.84$2M94,914Mar 2, 2026
Feb 26, 2026Mazelsky Jonathan JayPresident and CEO, Directoropen-market sale1,095$651.49$713K104,556Mar 2, 2026
Feb 26, 2026Mazelsky Jonathan JayPresident and CEO, Directoropen-market sale1,281$650.67$834K105,651Mar 2, 2026
Feb 26, 2026Mazelsky Jonathan JayPresident and CEO, Directoroption exercise23,326$141.60$3M106,932Mar 2, 2026
Feb 26, 2026Mazelsky Jonathan JayPresident and CEO, Directoropen-market sale2,589$663.04$2M83,606Mar 2, 2026
Feb 26, 2026Mazelsky Jonathan JayPresident and CEO, Directoropen-market sale1,000$662.16$662K86,195Mar 2, 2026
Feb 26, 2026Mazelsky Jonathan JayPresident and CEO, Directoropen-market sale1,200$661.10$793K87,195Mar 2, 2026

Full insider history for IDEXX Laboratories, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

2 of the tracked managers held IDXX in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded IDXX by quarter.

FundManagerQuarterValueSharesWeightMove
FundsmithTerry SmithQ2 2026$537M1M3.93%trimmed −30.4%
Baron Capital GroupRon BaronQ2 2026$1.0B2M1.56%added +21.0%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
IDEXX LABORATORIES INC /DE, CIK 874716 on EDGAR
Extract generated
August 28, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold, CostOfRevenue
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): not filed
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated August 28, 2026.

JSON file
/data/financials/IDXX.json